Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 6 months history of moderate or severe PPP, as defined by PPPASI ≥12 and PPPGA ≥3 at screening~* Males and females must be willing to use birth control as indicated~Exclusion Criteria:~* Moderate to severe psoriasis covering ≥10% of total body surface area (BSA) at screening~* Breastfeeding or pregnant~* Known immunodeficiency or subject is immunocompromised~* Active/latent infection with HBV, HCV, HIV, SARS-CoV-2 or TB~* Any topical medications for PPP excluding emollients within two weeks of randomization and systemic therapies (including phototherapy) within 4 weeks of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- RIST4721 400 mg (Type: EXPERIMENTAL): RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
- RIST4721 200 mg (Type: EXPERIMENTAL): RIST4721 200 mg: 2 active (100 mg) tablets + 2 placebo tablets once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: 4 placebo tablets once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).